January 9, 2007 

Santa Fe, NM & Worcester, MA - CytoDyn, Inc. (PK: CYDY) has appointed Shan Lu, MD, PhD, to its Scientific Advisory Board. Dr. Lu, who is a Professor of Medicine at the University of Massachusetts Medical School (UMMS) in Worcester, Massachusetts, is the lead inventor of the DNA-based pre-flu vaccine being developed by AITI, a wholly owned subsidiary of CytoDyn, Inc. The pre-flu vaccine is designed to provide protection against multiple strains of the flu virus, including the seasonal flu and the bird flu, all in one shot that can be given at any time of the year. 

Dr. Lu is an expert on novel vaccine development and is one of the early pioneers in the development of DNA-based vaccine technology. He has published extensively on vaccines targeting many of the major pathogens of our time including plague, smallpox, anthrax, SARS and flu.  He is Director of Nucleic Acid Vaccines at UMMS, one of the fastest growing academic health and biomedical research centers in the country. 

Forward looking statements are statements that are not historical facts. The Company's management makes forward looking statements concerning the Company's expected future operations, performance and other developments. These forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. There can be no assurance that such risks and uncertainties, or other factors, will not affect the accuracy of such forward-looking statements. It is impossible to identify all factors that could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, government regulation, managing and maintaining growth, victimization by white-collar offenders, and the effects of adverse publicity, litigation, competition, and other factors that may be identified from time to time in the Company's announcements. 


UMass Medical School, Kelly Bishop, 508-856-2000
CytoDyn, Stacia Andrews, 505-988-5520